Company Profile

Industry Sector: Biomarkers

Company Overview: Using its proprietary data mining technology, GeneGo has discovered and validated a set of gene expression biomarkers which divide breast cancer patients into clinically distinct groups (clusters). Every group feature differential expression of certain genes, clinical outcome and response to treatment. The Company now conducts a large retrospective validation study with Mayo Clinic, followed by product development and seeking FDA approval.

Target Market(s): Major hospitals and individual oncologists worldwide.

Management

Leadership:
Yuri Nikolsky, CEO
Tatiana Nikolskaya, President, Chief Scientific Officer
Andrej Bugrim, Chief Operating Officer
Julie Bryant, VP Business Development

Key Value Drivers

Technology: GeneGo developed a state-of-the art proprietary “systems reconstruction” technology for the analysis of high-throughput biological data. Disease-specific biomarkers discovery is a primary application of this technology. As soon as the set of markers is determined, they proceed through validation studies and product development phases. GeneGo technology is applicable for most of other cancers

Competitive Advantage: GeneGo breast cancer biomarkers over-perform the existing multi-variant genetic tests.

Plan & Strategy: seeking equity funding for product development, FDA approval and marketing

*Technology funded by two NCI grants and being commercialized under the NIH-CAP

Product Pipeline

- Retrospective study at Mayo Clinic: 200 patients
- Additional validation study: 200 – 400 patients
- US FDA approval process for breast cancer markers
- Biomarkers discovery program for ovarian, colorectal, prostate, lung cancers

Timeline:
- 0 months
- 6 months
- 12 months
- 18 months